Articles by tag: vepdegestrant

Vepdegestrant: FDA approved the first PROTAC degrader

FDA approved Vepdegestrant — the first protein degrader tablet for ESR1-mutant breast cancer. PFS 5 months vs 2.1 for fulvestrant. Learn why this is a paradigm shift.

Vepdegestrant: the first breast cancer protein degrader

FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.

PROTAC drug vepdegestrant approved for breast cancer

FDA has approved the first PROTAC drug vepdegestrant (Veppanu) for the treatment of breast cancer. Learn how proteolysis-targeting chimera reduces the risk of progression by 43% and opens a new era in oncology.